Annual incidence rates of serious and non-serious ocular drug-related AEs and ocular AEs of special interest using a 30 day risk period (Treated eyes of safety patients*)
| Incidence rate | Number of events | Treated eye-time-at risk, years | Value | 95% CI | |
| Lower limit | Upper limit | ||||
| Drug-related AEs | |||||
| Serious, overall | 1 | 435.1978 | 0.0023 | 0 | 0.0068 |
| Non-serious, overall | 9 | 435.1978 | 0.0207 | 0.0072 | 0.0342 |
| AEs of special interest | |||||
| Serious, overall | 1 | 435.1978 | 0.0023 | 0 | 0.0068 |
| Non-serious, overall | 4 | 435.1978 | 0.0092 | 0.0002 | 0.0182 |
Lower limits less than 0 were set to 0.
*Consisted of all enrolled patients who signed the informed consent, received at least one dose of study drug and had at least one postbaseline safety assessment.
AE, adverse event.